CD3D and severe combined immunodeficiency: Finally, ABEs have been recently used for the targeted correction of CD3D C202T, a mutation causing CD3δ severe combined immunodeficiency (SCID) in Jurkat T-cells and in CD34+ HSPCs leading to a more efficient CD3 repair compared to a CRISPR-Cas9 correction via homologous recombination [78].